|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 allele is associated with an increased risk of developing carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
|
31784043 |
2020 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Among the severe cADRs, HLA-B*57:01(OR = 11.00 95% CI: 1.41-85.81) and HLA-DRB1*07:01 (OR = 7.25; 95% CI: 1.09-48.18) were noted to be significantly associated with CBZ-induced Stevens Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN); HLA-B *51:01 was associated with drug reaction eosinophilia and systemic symptoms (DRESS) caused by PHT (OR = 6.90; 95% CI: 1.38-34.29).
|
30826555 |
2019 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Allergic drug reactions are unpredictable; nevertheless, there is increased risk of drug hypersensitivity in (1) patients with cystic fibrosis who receive antibiotics; (2) patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) who receive trimethoprim-sulfamethoxazole or if human leukocyte antigen (HLA)-B*5701+ and receive the antiretroviral agent abacavir; (3) other genetically susceptible populations, e.g., Han-Chinese with HLA-B*1502+ who develop Stevens-Johnson syndrome and toxic epidermal necrolysis from carbamazepine, with HLA-B*5801+ who are at increased risk for such reactions from allopurinol, those with HLA-A*32:01 and receive vancomycin and develop drug reaction with eosinophilia and systemic symptoms syndrome; and (4) patients with a history of compatible allergic reactions to the same medication, similar class, or potentially unrelated medication.
|
31690398 |
2019 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine.
|
29392710 |
2018 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Due to the significant risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the use of carbamazepine is not recommended in patients carrying the human leukocyte antigen B (HLA-B) *15:02 allele.
|
28440597 |
2018 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Studies found a strong association between allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and the HLA-B*58:01 allele.
|
29176400 |
2018 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.
|
29642234 |
2018 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The presence of HLA-B*15:02 and CYP2C9 *2 or *3 in the same patient increases the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis; hence, PHT should not be prescribed in these patients.
|
29636628 |
2018 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand.
|
29706602 |
2018 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Positive HLA-B*5801 carriers are at greater risk of experiencing rare but severe allopurinol hypersensitivity syndrome (AHS) [i.e., Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]; however, HLA-B*5801 prevalence and AHS risk vary by race/ethnicity.
|
27916277 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 is a known biomarker for carbamazepine (CBZ)-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) in some ethnic populations.
|
28205426 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
For example, it is well-established that HLA-B*15:02 and HLA-B*57:01 are associated with carbamazepine-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and abacavir-induced hypersensitivity/flucloxacillin-induced liver injury, respectively.
|
28017537 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis.
|
28358139 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population.
|
28570299 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 was confirmed as strongly associated with carbamazepine-induced Stevens-Johnson syndrome (<i>p</i> = 5.63 × 10<sup>-15</sup>).
|
28476759 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Screening for <i>HLA-B*15:02</i> is mandated in patients from South East Asia because of a strong association with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
|
28203102 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
For example, patients of Han-Chinese descent carrying the HLA-B*1502 allele are at an increased risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) if given carbamazepine.
|
28553132 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
|
28062682 |
2017 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
A decision tree model was constructed to incorporate the real-world data on AED prescription patterns, incidences of AED-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), costs of AED treatments, SJS/TEN treatment, and HLA-B*15:02 testing, and quality of life.
|
26888992 |
2016 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HLA-B∗15:02 is known as a biomarker for carbamazepine (CBZ) induced Steven-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) in some Asian populations.
|
27060780 |
2016 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Screening for the HLA-B*15:02 allele has been recommended to prevent carbamazepine (CBZ) - induced Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in individuals with Asian ancestry.
|
27544047 |
2016 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome.
|
27020614 |
2016 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*15:02.
|
27096699 |
2016 |
|
Stevens-Johnson Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities.
|
24777842 |
2015 |
|
Stevens-Johnson Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis.
|
25428396 |
2015 |